1. Home
  2. EMN vs NUVL Comparison

EMN vs NUVL Comparison

Compare EMN & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Chemical Company

EMN

Eastman Chemical Company

N/A

Current Price

$67.59

Market Cap

8.0B

Sector

Industrials

ML Signal

N/A

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

N/A

Current Price

$100.04

Market Cap

8.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EMN
NUVL
Founded
1920
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
8.1B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
EMN
NUVL
Price
$67.59
$100.04
Analyst Decision
Buy
Strong Buy
Analyst Count
14
15
Target Price
$78.57
$135.33
AVG Volume (30 Days)
1.3M
427.0K
Earning Date
04-30-2026
05-27-2026
Dividend Yield
4.85%
N/A
EPS Growth
N/A
N/A
EPS
4.10
N/A
Revenue
$8,752,000,000.00
N/A
Revenue This Year
$1.75
N/A
Revenue Next Year
$3.32
$1,064.25
P/E Ratio
$16.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$56.11
$55.54
52 Week High
$94.11
$113.02

Technical Indicators

Market Signals
Indicator
EMN
NUVL
Relative Strength Index (RSI) 30.66 44.59
Support Level $66.44 $98.37
Resistance Level $70.51 $107.13
Average True Range (ATR) 2.73 3.75
MACD -1.32 -0.14
Stochastic Oscillator 4.82 24.54

Price Performance

Historical Comparison
EMN
NUVL

About EMN Eastman Chemical Company

Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: